- Home
- XPEL vs ARQT Comparison
XPEL vs ARQT Comparison
Compare XPEL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- ARQT
- Stock Information
- Founded
- XPEL 1999
- ARQT 2016
- Country
- XPEL United States
- ARQT United States
- Employees
- XPEL N/A
- ARQT N/A
- Industry
- XPEL Industrial Specialties
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- ARQT Health Care
- Exchange
- XPEL Nasdaq
- ARQT Nasdaq
- Market Cap
- XPEL 1.2B
- ARQT 1.1B
- IPO Year
- XPEL N/A
- ARQT 2020
- Fundamental
- Price
- XPEL $40.20
- ARQT $14.93
- Analyst Decision
- XPEL Buy
- ARQT Strong Buy
- Analyst Count
- XPEL 2
- ARQT 4
- Target Price
- XPEL $49.00
- ARQT $15.50
- AVG Volume (30 Days)
- XPEL 121.9K
- ARQT 2.2M
- Earning Date
- XPEL 02-20-2025
- ARQT 02-25-2025
- Dividend Yield
- XPEL N/A
- ARQT N/A
- EPS Growth
- XPEL N/A
- ARQT N/A
- EPS
- XPEL 1.75
- ARQT N/A
- Revenue
- XPEL $418,411,000.00
- ARQT $138,708,000.00
- Revenue This Year
- XPEL $8.08
- ARQT $208.32
- Revenue Next Year
- XPEL $13.97
- ARQT $48.56
- P/E Ratio
- XPEL $22.93
- ARQT N/A
- Revenue Growth
- XPEL 13.32
- ARQT 182.84
- 52 Week Low
- XPEL $30.75
- ARQT $2.99
- 52 Week High
- XPEL $60.49
- ARQT $15.79
- Technical
- Relative Strength Index (RSI)
- XPEL 34.03
- ARQT 66.84
- Support Level
- XPEL $39.48
- ARQT $14.43
- Resistance Level
- XPEL $44.50
- ARQT $15.79
- Average True Range (ATR)
- XPEL 1.46
- ARQT 1.13
- MACD
- XPEL -0.58
- ARQT 0.12
- Stochastic Oscillator
- XPEL 9.96
- ARQT 76.88
About XPEL XPEL Inc.
XPEL Inc is a provider of protective films and coatings, including automotive paint protection film, surface protection film, automotive and commercial/residential window films, and ceramic coatings. The company has a network of trained installers and proprietary DAP software, dedicated to exceeding customer expectations by providing quality products, customer service, technical support, and world-class training. The majority of revenue is derived from the United states.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.